More than 15 years have passed since the successful mapping of the human genome. Many at the time believed that this advancement would lead to treatments for cancer and many other diseases that would be customized to individual patients. But despite the many advances made in cancer treatment the disease still claims over 600,000 American lives each year.
The potential benefits to cancer treatment that are promised by knowledge of genomic sequencing have gone largely unrealized. For the most part, the treatment of cancer today closely resembles the methodologies of a quarter-century ago. Thus far, the health care system has failed to develop a system to efficiently pair molecular data collected to a patient’s therapeutic data for the advancement of individual treatment plans.
The factor that seems to drive this problem is the data is simply not being collected. The combined total of the two largest public datasets contains data for less than 20,000 patients. Hospitals and cancer centers do not have the resources to facilitate a cost-effective manner for sequencing patients. And even if the resources were present most facilities have a patient count so low that it would take much too much time to collect enough data to be relevant.
I started Tempus to address these issues. I saw the benefit a health-tech company that brings technology and big data together could have in improving care for cancer patients. Tempus provides cancer doctors the necessary resources to provide patients with personalized treatment programs.
Tempus employs a highly qualified team of scientists and software engineers to develop analytical tools needed within hospital infrastructures to provide support for physician’s whose patients are in need of more non-conventional treatment remedies.
Hospitals have caught on fast to the benefits of working with Tempus as evidenced by the rapid growth in the number of hospitals making effective use of the company’s software. Tempus has recently entered into a partnership with Northwestern university’s Robert H Lurie Comprehensive Cancer Center.
It is the ultimate goal of Tempus to assure that each new cancer patient is the benefits of treatment received by patients before them. Tempus seeks to accomplish this goal by providing cancer physicians with a technological system that improves its own intelligence with additional data.
The time has come for health care providers to be given the tools they need to individualize the treatment of this disease.
About Eric Lefkofsky
Eric Lefkofsky is co-founder and acting CEO at Tempus. Tempus provides physicians with the interactive analytical technology needed to individualize cancer treatments for patients. Before working with Tempus, Lefkofsky had already accomplished much in his storied career as a businessman and entrepreneur.
Eric Lefkofsky co-founded both Groupon, a leading e-commerce site, and Uptake Technologies, a company that provides predictive analytics to some of the largest global industries.
Lefkofsky completed his undergraduate studies at the University of Michigan where he would also receive a law degree.
Eric and his wife Liz co-chair the Lefkofsky Family Foundation, an initiative that seeks to enhance the lives of the communities it serves.